Efficacy of Cr-51-EDTA clearence to tailor a carboplatin therapeutic regimen in ovarian cancer patients

Aim- The aim of this study was to evaluate the efficacy of Cr-51-EDTA clear ance to tailor the carboplatin dose in two different therapeutic regimens o f advanced epithelial ovarian cancer. Materials and Methods - 24 patients e ntered the study, eight treated by carboplatin (C) alone and six by C and p aclitaxel (P). The dose of C was calculated from the Calvert formula [DOSE( mg) = desired AUC x (GFR+25)] based on the Glomerular filtration rate (GFR) figure; in our protocol desired Area under the curve (AUC) figure was 5,mg lml x min. The method used to calculate the GFR requires only 4 blood sampl es taken in the late part of the disappearance plasmatic curve and conjugat es accuracy to an acceptable clinical compliance. Results - In only 5 cours es a significant hematological toxicity (HT) was present (4 courses grade 2 , 1 course grade 3); it was necessary to delay only 2 courses; no treatment wets discontinued because of HT. Conclusion - We concluded that there is n o summation toxicity of C and P if administer ed simultaneously and that th e assessment of GFR by (CI)-C-51-EDTA clearance is an optimal tool to predi ct an acceptable toxicity.